PentaOmix
Shedding Light on Cancer - Diagnosing cancer better and faster using hyperspectral data & AI
Company Overview
Snapshot
Founded in July 2020 by Boaz Brill and Yuval Garini, PentaOmix operates with 1–10 employees. The company has raised $2.27 million across one funding round. In February 2022, PentaOmix secured a grant from the ATTRACT Project.
Business overview
PentaOmix is developing a novel digital pathology modality to enhance cancer diagnosis and treatment matching. The company's system leverages hyperspectral imaging and AI algorithms to provide a deeper understanding of tumor microenvironments and progression. This technology aims to shorten development times for cancer drug biomarkers, improve clinical study screening, and eventually serve as a companion diagnostic in hospitals, operating within the Health Tech & Life Sciences sector, specifically in Digital Medical Diagnostics.
Company Intelligence Q&A
- What is PentaOmix's core technology?
- PentaOmix utilizes hyperspectral imaging combined with AI algorithms to analyze tumor microenvironments, aiming to improve cancer diagnosis and personalize treatment selection.
- When was PentaOmix founded?
- PentaOmix was founded in July 2020.
- Who are the founders of PentaOmix?
- PentaOmix was co-founded by Boaz Brill, who serves as CEO, and Yuval Garini, who is the CSO.
- What is PentaOmix's primary product?
- PentaOmix's primary product is PentaVision, a system designed for advanced cancer diagnostics.